Browse life science companies in Cambridge, home to one of Europe's leading biotechnology and life science ecosystems.
Mechanobiology platform for target discovery and validation
Mechanome Bio is a Cambridge-based company developing a mechano-transcriptomics platform for biomarker and drug target discovery. The platform combines spatial multi-omics data from human tissue samples with mechanical tissue profiling and in silico tissue modelling to identify targets linked to changes in tissue…
Computationally designed broadly protective vaccines against pandemic viruses
DIOSynVax is a clinical-stage biotechnology company developing broadly protective vaccines using a computational antigen design platform. The company's technology applies protein structure modelling and immune optimisation to engineer synthetic vaccine antigen payloads targeting conserved regions of viruses, enabling…
AI-enabled personalised dosing for drug-digital combination therapies
Closed Loop Medicine develops combination products integrating pharmaceutical therapies with AI-powered digital companions to personalise drug dosing for chronic conditions. Its platform applies pharmacometric modelling and patient response data to optimise treatment regimens. The pipeline includes co-packaged drug…
Genome-editing platform mapping cancer drug resistance and druggable vulnerabilities
BASE Rx is a Wellcome Sanger Institute spin-out applying genome-editing and DNA sequencing technologies to cancer drug discovery. The company maps single-base genetic variants to identify druggable vulnerabilities in cancer genes and predict the DNA changes that drive resistance to cancer therapies. BASE Rx aims to…
Precision therapeutics targeting fibrosis using multi-omics
Forth Therapeutics develops precision medicines intended to target the cellular mechanisms driving organ fibrosis. Its discovery platform combines single-cell and spatial genomics with patient-derived tissue data, including a large human liver disease dataset. These insights help identify disease-associated cells and…
End-to-end antibody discovery and development services for global biopharma
FairJourney Biologics is a contract research organisation providing integrated antibody discovery, engineering, production and characterisation services to pharmaceutical and biotechnology companies worldwide. The company combines phage display and mammalian display technologies across immune and naïve antibody…
Organ-specific liquid biopsy tests for early cancer detection
Mursla Bio is a diagnostics company developing blood-based tests for early cancer detection using extracellular vesicle biology. Its platform isolates organ-specific extracellular vesicles from blood and applies multi-omics profiling and machine learning to identify disease biomarkers without tissue biopsy. Its lead…
Targeted oral drug delivery platform for cancer, CNS and respiratory disease
TRX Biosciences is a biotechnology company developing a targeted oral drug delivery platform, enabling therapies to reach specific organs, cells and tissues for cancer, central nervous system, respiratory and immune system diseases. The company's technology is licensed to partner companies for use in their own drug…
Regulatory-compliant medical AI software and connected device development
Camgenium is a medical technology software company specialising in the development and deployment of AI-driven medical device software and connected hardware. Operating to ISO 13485, ISO 27001 and GxP standards, the company offers end-to-end services spanning product concept, development, production, and deployment.…
Computational chemistry software and consulting for small molecule discovery
Cresset Biomolecular Discovery is a UK software and consulting company providing computational chemistry solutions for small molecule drug discovery and design. Its patented field technology evaluates molecules using surface properties rather than 2D structural similarity, enabling virtual screening, scaffold hopping,…
AI-designed extended-expression RNA therapeutics for cardio-metabolic disease
ScionxBio, formerly Eleven Therapeutics, is a biotechnology company developing xRNA, a chemically expanded RNA modality engineered to extend protein expression from days to months. Combinatorial chemistry and deep learning are combined to design molecules with enhanced stability and reduced immune sensing, enabling…
Diverse oncology datasets for AI-driven precision medicine research
CureCollect is a life science data company sourcing multimodal oncology datasets for precision medicine and artificial intelligence research. It collaborates with hospitals and laboratories to assemble pathology images, genomic and transcriptomic data, longitudinal clinical records and treatment outcomes from diverse…
Human proteome microarrays and protein array screening services
Cambridge Protein Arrays supplies human proteome microarrays and specialist screening services for researchers. Its HuProt arrays contain thousands of full-length human proteins, enabling antibody specificity testing, autoantibody profiling and investigations of molecular interactions. Researchers can obtain arrays or…
Small-molecule drugs targeting cellular ageing and senescence
Five Alarm Bio Limited is a biotechnology company discovering small-molecule therapies for diseases associated with ageing. Its research targets chemical damage that accumulates inside cells, aiming to reinforce protective mechanisms and delay cellular senescence rather than destroy senescent cells. Candidate…
Interdisciplinary institute studying the regulatory systems of plant development
Sainsbury Laboratory Cambridge University is a research institute studying the regulatory systems underlying plant growth and development. The Laboratory combines experimental biology with computational modelling, bringing together biologists, physicists and mathematicians to understand how plant hormones, gene…
Solid form sciences and API development for drug candidates
Veranova's Cambridge site is a centre of excellence in solid form and particle engineering, operating under the Pharmorphix brand. The facility provides polymorph screening, salt selection, co-crystallisation, chiral separations, and process scale-up services to pharmaceutical and biotechnology customers. Part of…
Multiomics platform for cancer biomarker discovery and diagnostics
Tagomics is a Cambridge-based biotech developing a multiomics platform for disease biomarker discovery and diagnostics. Its platform integrates genomics, epigenomics and fragmentomics with advanced bioinformatics and machine learning to identify disease-associated DNA markers from blood and other biological sources.…
Fragment and structure-based drug discovery services
Vernalis (R&D) is a Cambridge-based contract drug discovery organisation specialising in fragment-based and structure-based drug discovery. The company integrates structural biology, biophysics, NMR spectroscopy, DNA-encoded library screening, medicinal chemistry, and computational approaches to identify and progress…
CASPAROV AI platform for targets in heterogeneous cancers
Enedra Therapeutics develops targeted cancer medicines designed to address genetic diversity within solid tumours, a major cause of treatment resistance. Its CASPAROV platform combines cancer genomics, AI and functional biology to identify survival mechanisms shared across heterogeneous tumour cells. These convergent…
G-quadruplex-targeting medicines for precision cancer treatment
Genome Therapeutics is a biotechnology company developing cancer medicines that target G-quadruplex DNA structures associated with tumour biology. Its approach builds on research into non-canonical DNA folding and how these structures influence gene regulation and cancer cell vulnerabilities. The company develops…